recent articles
The liquid biopsy has been developed by Datar Cancer Genetics to help diagnose brain tumors where a conventional biopsy is not possible. A prospective, blinded study by a research team at the Imperial College, London showed very high...
December 15, 2022 | Personalis and the University of California, San Francisco (UCSF) have announced a collaboration that will deploy a personalized liquid biopsy-based research use only (RUO) assay for a study of patients with colorectal...
nRichDX: The Revolution Circulating Free Total Nucleic Acid (cfTNA) Kit™ and cfDNA Reference Standard products are designed to advance liquid biopsy application development. IRVINE, Calif., October 24, 2022 – nRichDX® has launched...
SpIntellx: Seasoned precision healthcare executive brings deep leadership, commercial and operational experience PITTSBURGH (PRWEB) MAY 16, 2022 -- B. Dusty Majumdar, Ph.D. has been appointed as the Chief Executive Officer (CEO) of SpIntellx,...
To help build out its own portfolio of artificial-intelligence-driven pathology tests, Quest Diagnostics has enlisted the help of Paige to develop a suite of products aimed at individual clinical oncologists as well as larger biopharma...
Grail’s Billion Dollar Bet for the Perfect Cancer Test
- Advocacy
- Anatomic Pathology
- Business
- Clinical Laboratories
- Clinical Pathology
- Conferences
- Current Affairs
- Data Management
- Device Manufacturers
- Digital Pathology News
- Education
- General Healthcare News
- Genetics
- Histology
- Laboratory Informatics
- Laboratory Management & Operations
- Liquid Biopsy
- Medical Research
- Molecular Pathology
- Pathology News
- Science
- Tissue banking
Thought this was worth sharing from MIT Technology Review. After attending ASCO last week what I thought might happen a year or two again actually has. Pathologists no longer have to worry about stepping out from behind the paraffin curtain...